Metabolism News and Research

Latest Metabolism News and Research

Orexigen Therapeutics announces data from CORDiabetes trial for Contrave

Orexigen Therapeutics, Inc. today announced data from the CORDiabetes trial for Contrave (naltrexone sustained release (SR)/bupropion SR) showing that after 56 weeks of treatment, overweight or obese patients with type 2 diabetes lost significantly more weight and achieved greater improvement in glycemic control than those treated with placebo.

28 Jun 2010

Arena's lorcaserin reduces body weight across patient subgroups

Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.

28 Jun 2010

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

Healthier cafeteria choices, longer and more intense periods of physical activity and robust in-school education programs can lower rates of obesity and other risk factors for type 2 diabetes, according to a national study called HEALTHY.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.

28 Jun 2010

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

The cause of diabetes during pregnancy is directly controlled by serotonin, a chemical produced by the body and normally known as a neurotransmitter, and is influenced by the amount of protein in the mother's diet early in pregnancy, according to new findings of an international team led by researchers at UCSF.

28 Jun 2010

Overview of scientific research on medical technology to combat anthrax threat

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.

25 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Study on effects of resveratrol on metabolism of microcebus murinus

Resveratrol is a natural substance that is widely studied, for its anti-ageing properties among other things. For the first time, work by a team in the "Mécanismes adaptatifs : des organismes aux communautés" Laboratory (CNRS/Muséum National d'Histoire Naturelle) has revealed that this compound reduces weight gain in lemurs. Such findings provide new information regarding the effects of resveratrol on energy metabolism and the control of body mass in primates. They may give a clearer understanding of the factors that govern obesity in humans. This study is published on 22 June 2010 in /BMC Physiology/.

25 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

24 Jun 2010

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.

24 Jun 2010

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.

24 Jun 2010

$Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors$

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.

23 Jun 2010

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

The Endocrine Society presented its Scientific Statement on menopausal hormone therapy Monday in San Diego, Calif. at ENDO 2010: The 92nd Annual Meeting & Expo.

23 Jun 2010

Metabolism News and Research

Latest Metabolism News and Research

Orexigen Therapeutics announces data from CORDiabetes trial for Contrave

Arena's lorcaserin reduces body weight across patient subgroups

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

Overview of scientific research on medical technology to combat anthrax threat

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Study on effects of resveratrol on metabolism of microcebus murinus

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech